Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Patterns of structural variation define prostate cancer across disease states
Meng Zhou, … , Srinivas R. Viswanathan, Gavin Ha
Meng Zhou, … , Srinivas R. Viswanathan, Gavin Ha
Published August 9, 2022
Citation Information: JCI Insight. 2022;7(17):e161370. https://doi.org/10.1172/jci.insight.161370.
View: Text | PDF
Research Article Genetics Oncology

Patterns of structural variation define prostate cancer across disease states

  • Text
  • PDF
Abstract

The complex genomic landscape of prostate cancer evolves across disease states under therapeutic pressure directed toward inhibiting androgen receptor (AR) signaling. While significantly altered genes in prostate cancer have been extensively defined, there have been fewer systematic analyses of how structural variation shapes the genomic landscape of this disease across disease states. We uniformly characterized structural alterations across 531 localized and 143 metastatic prostate cancers profiled by whole genome sequencing, 125 metastatic samples of which were also profiled via whole transcriptome sequencing. We observed distinct significantly recurrent breakpoints in localized and metastatic castration-resistant prostate cancers (mCRPC), with pervasive alterations in noncoding regions flanking the AR, MYC, FOXA1, and LSAMP genes enriched in mCRPC and TMPRSS2-ERG rearrangements enriched in localized prostate cancer. We defined 9 subclasses of mCRPC based on signatures of structural variation, each associated with distinct genetic features and clinical outcomes. Our results comprehensively define patterns of structural variation in prostate cancer and identify clinically actionable subgroups based on whole genome profiling.

Authors

Meng Zhou, Minjeong Ko, Anna C.H. Hoge, Kelsey Luu, Yuzhen Liu, Magdalena L. Russell, William W. Hannon, Zhenwei Zhang, Jian Carrot-Zhang, Rameen Beroukhim, Eliezer M. Van Allen, Atish D. Choudhury, Peter S. Nelson, Matthew L. Freedman, Mary-Ellen Taplin, Matthew Meyerson, Srinivas R. Viswanathan, Gavin Ha

×

Figure 3

Modes of AR activation in mCRPC.

Options: View larger image (or click on image) Download as PowerPoint
Modes of AR activation in mCRPC.
(A) Copy number of AR gene and its enha...
(A) Copy number of AR gene and its enhancer (~624 kb upstream) for mCRPC cohort samples after adjustment by tumor purity and sample ploidy normalization. Data shown for samples with available AR gene expression data. Left: Copy number of AR and its enhancer is shown in log2 scale, colored based on AR gene expression level (transcripts per million [TPM]). Right: Excerpt of figure highlighting AR expression for samples with lower copy number values. (B) AR expression for AR locus copy number status for 122 samples with available AR gene expression data. ANCOVA test was performed to account for tumor purity and ploidy as covariates. Tukey’s HSD P values for pairwise comparisons between groups with AR locus amplification status and groups with no amplification. (C) Patterns of rearrangements involving the AR locus in 143 mCRPC samples. Presence of specific alteration events and complex rearrangements (black) was predicted automatically and manually curated. AR gene expression shown (blue shades) for the same samples in B; samples with no available expression data are indicated in gray. (D–H) Representative examples of each category. Complex and simple rearrangement patterns involving the AR locus, including focal duplication events on AR enhancer (D), intragenic amplification event leading to a breakpoint within AR between exons 4 and 5 (E), chromosome-level chromothripsis events involving AR and enhancer (F), arm-level chromothripsis coinciding with AR amplification by break-fusion-break cycle (G), and extrachromosomal DNA amplicon including AR and enhancer (H). AR gene boundary (green) and its enhancer (yellow) are shown. Concave arcs, intrachromosomal SV events; convex arcs, interchromosomal SV events. Copy number values represent 10 kb bins and have been tumor purity corrected.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts